GALLIUM GA 68 EDOTREOTIDE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for GALLIUM GA 68 EDOTREOTIDE (GALLIUM GA 68 EDOTREOTIDE).
Gallium Ga 68 edotreotide is a radiopharmaceutical analog of somatostatin that binds to somatostatin receptors, particularly subtype 2 (SSTR2), which are overexpressed on neuroendocrine tumor cells. After binding, internalization occurs, and the gallium-68 isotope emits positrons for PET imaging.
| Metabolism | Gallium Ga 68 edotreotide is not metabolized; it undergoes renal excretion. The gallium-68 isotope decays by positron emission with a half-life of 68 minutes. |
| Excretion | Renal: >90% unchanged in urine within 24 hours; biliary/fecal: <2%. |
| Half-life | Terminal elimination half-life: 0.5–2.5 hours (mean 1.2 hours); clinically allows same-day imaging after injection. |
| Protein binding | ~20% bound to plasma proteins (albumin and globulins). |
| Volume of Distribution | Vd: 0.3–0.5 L/kg; indicates distribution mainly in extracellular fluid and receptor-rich tissues. |
| Bioavailability | Not applicable (IV administration only); 100% bioavailability via IV. |
| Onset of Action | IV: Uptake in somatostatin receptor-positive tissues within minutes; peak tumor-to-background ratio at 90–120 minutes post-injection. |
| Duration of Action | Imaging window: 1–4 hours post-injection for optimal lesion detection; residual activity low by 24 hours. |
148-259 MBq (4-7 mCi) IV once for PET imaging.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for renal impairment; GFR <30 mL/min use with caution due to limited data. |
| Liver impairment | No specific Child-Pugh based adjustments; use standard dosing in mild-to-moderate hepatic impairment, caution in severe impairment due to lack of data. |
| Pediatric use | 2 MBq/kg (0.054 mCi/kg) IV, minimum 10 MBq (0.27 mCi), maximum 200 MBq (5.4 mCi); adjust for weight. |
| Geriatric use | No specific adjustment; use standard adult dosing, consider age-related renal decline and comorbidities. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for GALLIUM GA 68 EDOTREOTIDE (GALLIUM GA 68 EDOTREOTIDE).
| Breastfeeding | Contraindicated during breastfeeding due to risk of radiation transfer to infant. No M/P ratio available; gallium-68 half-life of 68 minutes permits brief interruption, but benefits of diagnostic use do not outweigh risks. |
| Teratogenic Risk | Category D: Positive evidence of human fetal risk. Ionizing radiation exposure to fetus, particularly during organogenesis (weeks 2-7) and second trimester, may cause growth retardation, malformations, and carcinogenesis. Risk higher with cumulative dose >0.1 Gy. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Hypersensitivity to gallium Ga 68 edotreotide or any of its components"]
| Precautions | ["Radiation exposure risk; ensure safe handling and disposal","Risk of allergic/hypersensitivity reactions (rare)","False-positive or false-negative results due to variable SSTR expression","Interference with somatostatin analog therapy (discontinue long-acting analogs 4 weeks before scan; short-acting analogs 24 hours before scan)"] |
Loading safety data…
| Fetal Monitoring |
| Monitor fetal radiation dose using AAPM/ACR guidelines; caution in women with potential pregnancy. Pre-administration verify pregnancy status via beta-hCG. Post-administration, document exposure and follow pregnancy outcome registry. |
| Fertility Effects | Potential gonadal radiation exposure may temporarily reduce fertility; long-term risk of gonadal damage from cumulative radiation. Men: possible oligospermia. Women: possible ovarian failure with high cumulative doses. |